CellectisALCLS
ALCLS logo
Fair Value
€6.5
Share price10 Dec
€2.8456.3% undervalued intrinsic discount
Loading
1Y27.44%
7D-6.20%

Allogeneic CAR T Pipeline And AstraZeneca Partnership Will Drive Long-Term Upside

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
10 Dec 25
Views
16
Not Invested

Fair Value vs Share Price

€6.5
vs €2.8456.3% undervalued intrinsic discount
PastFuture-109m83m2014201720202023202520262028Revenue US$80.5mEarnings US$33.1m
-0.8%
Revenue growth
41.2%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Cellectis

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Undervalued with excellent balance sheet.

Market cap€206.6m
PB5.8x
Estimated Growth14.8%
Dividend YieldN/A
Full analysis

CEO & management

Andre Choulika
CEO
6.2yrs
CEO Tenure

A clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.